pharmacie et médicaments – Myélome multiple : déremboursement de traitements innovants

This written question asks about the reimbursement status of innovative treatments for multiple myeloma, a type of blood cancer. It highlights concerns regarding access to these new therapies for patients in France. The question seeks clarification on the criteria and decisions made regarding the de-listing or non-reimbursement of these crucial medications, potentially affecting patients' ability to afford and receive them.